longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

JW THERAP-B

02126

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.13, below the reasonable range, cheaper than 80.08% of the time in the past 1 years, and the industry ranks 29/78, the industry Median -5.79.

-2.13xP/E
HK$2.00Stock price
HK$-0.94Earnings per share
-2.13xP/E
Stock priceHK$2.00Earnings per shareHK$-0.94

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.54x
Typical range
-2.12x–-1.21x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0159318477636

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
09926HKAKESO
-78.79x84.17%HK$87.74B
09688HKZAI LAB
-14.68x505.86%HK$21.66B
01877HKJUNSHI BIO
-38.33x84.85%HK$17.74B
07666HKMETIS TECHBIO-P
-40.68x96.70%HK$16.56B
09606HKDUALITYBIO-B
-9.89x83.47%HK$16.39B
06855HKASCENTAGE
-6.88x18.21%HK$11.63B
02627HKAB&B BIO-TECH-B
-46.87x--HK$11.54B
09887HKLEADS BIOLABS-B
-36.95x9.00%HK$11.36B
02595HKGENFLEET-B
-6.46x78.96%HK$9.78B
02616HKCSTONE PHARMA-B
-19.67x1.96%HK$9.49B
01672HKASCLETIS-B
-13.81x78.59%HK$9.40B
01952HKEVEREST MED
-149.89x324.61%HK$9.31B
02493HKMABWELL-B
-8.51x--HK$9.21B
06938HKRIBOLIFE-B
-43.55x29.88%HK$8.51B
09966HKALPHAMAB-B
-37.63x--HK$7.63B
02171HKCARSGEN-B
-72.22x51.12%HK$7.42B
01779HKLONGBIO-B
-28.39x--HK$7.07B
02335HKMICOT PHARMA-B
-16.57x37.50%HK$6.95B
06872HKTENNOR THERAP-B
-40.13x--HK$6.44B
02256HKABBISKO-B
-11.36x300.95%HK$6.10B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.